Synthesis of Novel (S)-3-(1-Aminoethyl)-8-pyrimidinyl-2-phenylisoquinolin-1(2H)-ones by Suzuki–Miyaura Coupling and Their Cell Toxicity Activities

A series of (S)-3-(1-aminoethyl)-8-pyrimidinyl-2-phenylisoquinoline-1(2H)-ones 3a–3k was synthesized in 40–98% yield through Suzuki–Miyaura coupling using Pd(PPh3)2Cl2, Sphos, and K2CO3 in THF/H2O mixed solvent. All newly synthesized compounds were evaluated for cell viability (IC50) against MDA-MB-231, HeLa, and HepG2 cells. The antitumor activities of 3a–3k were improved when various pyrimidine motifs were introduced at position C-8 of the isoquinolinone ring.

[1]  Hajime Ito,et al.  Air- and moisture-stable Xantphos-ligated palladium dialkyl complex as a precatalyst for cross-coupling reactions. , 2019, Chemical communications.

[2]  D. A. Rodrigues,et al.  Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases , 2019, Pharmaceuticals.

[3]  Rebecca E. Meadows,et al.  Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat , 2018, Organic Process Research & Development.

[4]  D. Roy,et al.  Recent Advances in Palladium‐Catalyzed Cross‐Coupling Reactions at ppm to ppb Molar Catalyst Loadings , 2018 .

[5]  C. Lindsley,et al.  Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. , 2017, Organic letters.

[6]  V. Palombella,et al.  Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. , 2016, ACS medicinal chemistry letters.

[7]  김성환,et al.  Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient , 2016 .

[8]  S. Sideris,et al.  Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR , 2016, ACS medicinal chemistry letters.

[9]  Jing Xu,et al.  Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping. , 2013, Bioorganic & medicinal chemistry.

[10]  C. Oliver Kappe,et al.  Microwave-assisted cross-coupling and hydrogenation chemistry by using heterogeneous transition-metal catalysts: an evaluation of the role of selective catalyst heating. , 2009, Chemistry.

[11]  A. Barker,et al.  AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts , 2009, Molecular Cancer Therapeutics.

[12]  M. Burke,et al.  A general solution for unstable boronic acids: slow-release cross-coupling from air-stable MIDA boronates. , 2009, Journal of the American Chemical Society.

[13]  S. Buchwald,et al.  Palladium-catalyzed Suzuki-Miyaura cross-coupling reactions employing dialkylbiaryl phosphine ligands. , 2008, Accounts of chemical research.

[14]  S. Buchwald,et al.  Highly efficient monophosphine-based catalyst for the palladium-catalyzed suzuki-miyaura reaction of heteroaryl halides and heteroaryl boronic acids and esters. , 2007, Journal of the American Chemical Society.

[15]  V. A. Glushkov,et al.  Synthesis of 1(2H)-Isoquinolones , 2002 .

[16]  G. C. Fu,et al.  Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions , 2000 .

[17]  S. Buchwald,et al.  Highly Active Palladium Catalysts for Suzuki Coupling Reactions , 1999 .

[18]  H. Cottam,et al.  Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. , 1999, Journal of medicinal chemistry.

[19]  T. Matsui,et al.  Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones. , 1992, Journal of medicinal chemistry.